Chemical Component Summary

Nameethyl 6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2-[(phenylsulfanyl)methyl]-1H-indole-3-carboxylate
Identifiersethyl 6-bromanyl-4-[(dimethylamino)methyl]-1-methyl-5-oxidanyl-2-(phenylsulfanylmethyl)indole-3-carboxylate
FormulaC22 H25 Br N2 O3 S
Molecular Weight477.42
TypeNON-POLYMER
Isomeric SMILESCCOC(=O)c1c(CSc2ccccc2)n(C)c3cc(Br)c(O)c(CN(C)C)c13
InChIInChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3
InChIKeyKCFYEAOKVJSACF-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count54
Chiral Atom Count0
Bond Count56
Aromatic Bond Count16

Drug Info: DrugBank

DrugBank IDDB13609 
NameUmifenovir
Groupsinvestigational
DescriptionUmifenovir is an indole-based, hydrophobic, dual-acting direct antiviral/host-targeting agent used for the treatment and prophylaxis of influenza and other respiratory infections.[A191475] It has been in use in Russia for approximately 25 years and in China since 2006. Its invention is credited to a collaboration between Russian scientists from several research institutes 40-50 years ago, and reports of its chemical synthesis date back to 1993.[A191475] Umifenovir's ability to exert antiviral effects through multiple pathways has resulted in considerable investigation into its use for a variety of enveloped and non-enveloped RNA and DNA viruses, including _Flavivirus_,[A191388] Zika virus,[A191391] foot-and-mouth disease,[A191394] Lassa virus,[A191403] Ebola virus,[A191403] herpes simplex,[A191409], hepatitis B and C viruses, chikungunya virus, reovirus, Hantaan virus, and coxsackie virus B5.[A191475,A191412] This dual activity may also confer additional protection against viral resistance, as the development of resistance to umifenovir does not appear to be significant.[A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational HIV therapies.[A191385,A191550,L12012]
SynonymsUmifenovir
IndicationUmifenovir is currently licensed in China and Russia for the prophylaxis and treatment of influenza and other respiratory viral infections.[A191475] It has demonstrated activity against a number of viruses and has been investigated in the treatment of _Flavivirus_,[A191388] Zika virus,[A191391] foot-and-mouth disease,[A191394] Lassa virus,[A191403] Ebola virus,[A191403] and herpes simplex.[A191409] In addition, it has shown _in vitro_ activity against hepatitis B and C viruses, chikungunya virus, reovirus, Hantaan virus, and coxsackie virus B5.[A191475,A191412] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for the prevention of COVID-19 caused by SARS-CoV-2 infections.[A191385,A191550]
Categories
  • Antiinfectives for Systemic Use
  • Antiviral Agents
  • Antivirals for Systemic Use
  • Cytochrome P-450 CYP1A2 Substrates
  • Cytochrome P-450 CYP2C9 Substrates
ATC-CodeJ05AX13
CAS number131707-25-0

Drug Targets

NameTarget SequencePharmacological ActionActions
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Dimethylaniline monooxygenase [N-oxide-forming] 3MGKKVAIIGAGVSGLASIRSCLEEGLEPTCFEKSNDIGGLWKFSDHAEEG...unknownsubstrate
Dimethylaniline monooxygenase [N-oxide-forming] 1MAKRVAIVGAGVSGLASIKCCLEEGLEPTCFERSDDLGGLWRFTEHVEEG...unknownsubstrate
Cytochrome P450 2E1MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLEL...unknownsubstrate
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682